Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PALB2 A1025R||Advanced Solid Tumor||sensitive||PARP Inhibitor (Pan)||Olaparib||Preclinical - Cell culture||Actionable||In a preclinical study, cells expressing PALB2 A1025R were sensitive to treatment with Lynparza (olaparib) in culture, demonstrating decreased cell survival (PMID: 31636395).||31636395|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|